Research & Development Laboratories near Codrington ON (70 Result(s))

CardioGenics is dedicated to develop more sensitive diagnostic test products to the IVD market. CardioGenics has started several developmental processes aimed to achieve its objective 'to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies'.CardioGenics' operating philosophy is that 'better diagnosis enhances the healthcare professionals' ability to provide better patient management which saves lives and reduces healthcare costs'. Fulfilling unmet clinical testing needs is the driving force behind CardioGenics' innovations.

CardioGenics is dedicated to develop more sensitive diagnostic test products to the IVD market. CardioGenics has started several developmental processes aimed to achieve its objective 'to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies'. operating philosophy is that 'better diagnosis enhances the healthcare professionals' ability to provide better patient management which saves lives and reduces healthcare costs'. Fulfilling unmet clinical testing needs is the driving force behind CardioGenics' innovations.

Often, pharmaceutical companies avoid new laboratory testing methodologies preferring to stick to established procedures for drug development so as to avoid any potential regulatory ambiguity. This tendency to avoid new methodologies and regulatory scrutiny sometimes leads to slower progress, higher costs and lower probability of new product approvals. Furthermore, some pharmaceutical firms severely restrict academic research-based modifications to established laboratory testing procedures in drug development because of their concern over triggering costly adjustments to the established regulatory framework.

Viventia is developing and advancing the next generation of human antibody-based therapeutics for use in oncology. Our approach combines the specificity of an antibody with the potency of a cytotoxic payload to provide targeted therapies for the safer and more efficacious treatment of cancer patients. Viventia has developed a potent payload, deBouganin, that when coupled to a targeting antibody can effectively kill cancer cells without harming normal cells. This differential targeting enhances the therapeutic potential of our drugs and provides prolonged clinical benefit. The versatile deBouganin payload has been chemically conjugated to full length antibodies as well as fused to numerous antibody fragments and has been found to be safe and efficacious in the clinic.